Decken, Cay-Benedict; Kleinert, Stefan; Englbrecht, Matthias; Karberg, Kirsten; Gauler, Georg; Ronneberger, Monika; Rapp, Praxedis; Schuch, Florian; Wendler, Joerg; Späthling-Mestekemper, Susanna; Kuhn, Christoph; Vorbrüggen, Wolfgang; Welcker, Martin; Bartz-Bazzanella, Peter: RhePort 1.3 enhances early identification of inflammatory rheumatic diseases: a prospective study in German rheumatology settings. In: Rheumatol Int, Bd. 45, Nr. 5, S. 129, 2025, ISSN: 1437-160X. @article{pmid40293492,
title = {RhePort 1.3 enhances early identification of inflammatory rheumatic diseases: a prospective study in German rheumatology settings},
author = {Cay-Benedict Decken and Stefan Kleinert and Matthias Englbrecht and Kirsten Karberg and Georg Gauler and Monika Ronneberger and Praxedis Rapp and Florian Schuch and Joerg Wendler and Susanna Späthling-Mestekemper and Christoph Kuhn and Wolfgang Vorbrüggen and Martin Welcker and Peter Bartz-Bazzanella},
doi = {10.1007/s00296-025-05861-z},
issn = {1437-160X},
year = {2025},
date = {2025-04-01},
journal = {Rheumatol Int},
volume = {45},
number = {5},
pages = {129},
abstract = {More efficient means of identifying patients with inflammatory rheumatic diseases (IRDs) could allow earlier diagnosis and treatment. The objective of this study was to evaluate the characteristics of a revised version of an online patient questionnaire-based self-referral tool, RhePort 1.3. This prospective study included adult patients with musculoskeletal complaints presenting for a first rheumatology visit at German RheumaDatenRhePort (RHADAR) rheumatology network centers. All patients completed the RhePort 1.3 questionnaire on patient characteristics and symptoms. Data from RhePort 1.3 were compared with historical data from previous versions. Of 614 patients, 225 (36.6%) were diagnosed with an IRD by a rheumatologist and 164/225 IRD patients (72.9%) had a RhePort 1.3 score > 1, the cut-off point used to determine the need for rheumatologic evaluation. A score > 1 was associated with an approximately two-fold higher IRD risk (odds ratio [95% confidence interval] of 1.98 [1.39, 2.83] vs ≤ 1) and had good sensitivity (73%) and moderate specificity (42%). Among patients referred through a standard referral pathway (n = 283), RhePort 1.3 scores > 1 in addition to physician referral were associated with increases in rheumatology-diagnosed IRD rates from 33.2% (physician referral only) to 45.7%. RhePort 1.3 had higher accuracy than earlier versions (54% vs 35%). We conclude that modest changes to the RhePort questionnaire resulted in increased accuracy. A score > 1 was associated with a doubled risk for an IRD and higher IRD rates in physician-referred patients. These data suggest that RhePort has the potential to streamline the rheumatologist's workload and improve resource use. Further modifications are required to improve specificity.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
More efficient means of identifying patients with inflammatory rheumatic diseases (IRDs) could allow earlier diagnosis and treatment. The objective of this study was to evaluate the characteristics of a revised version of an online patient questionnaire-based self-referral tool, RhePort 1.3. This prospective study included adult patients with musculoskeletal complaints presenting for a first rheumatology visit at German RheumaDatenRhePort (RHADAR) rheumatology network centers. All patients completed the RhePort 1.3 questionnaire on patient characteristics and symptoms. Data from RhePort 1.3 were compared with historical data from previous versions. Of 614 patients, 225 (36.6%) were diagnosed with an IRD by a rheumatologist and 164/225 IRD patients (72.9%) had a RhePort 1.3 score > 1, the cut-off point used to determine the need for rheumatologic evaluation. A score > 1 was associated with an approximately two-fold higher IRD risk (odds ratio [95% confidence interval] of 1.98 [1.39, 2.83] vs ≤ 1) and had good sensitivity (73%) and moderate specificity (42%). Among patients referred through a standard referral pathway (n = 283), RhePort 1.3 scores > 1 in addition to physician referral were associated with increases in rheumatology-diagnosed IRD rates from 33.2% (physician referral only) to 45.7%. RhePort 1.3 had higher accuracy than earlier versions (54% vs 35%). We conclude that modest changes to the RhePort questionnaire resulted in increased accuracy. A score > 1 was associated with a doubled risk for an IRD and higher IRD rates in physician-referred patients. These data suggest that RhePort has the potential to streamline the rheumatologist's workload and improve resource use. Further modifications are required to improve specificity. |
Kleinert, S.; Schuch, F.; Rapp, P.; Ronneberger, M.; Wendler, J.; Sternad, P.; Popp, F.; Bartz-Bazzanella, P.; Decken, C.; Karberg, K.; Gauler, G.; Wurth, P.; Spathling-Mestekemper, S.; Kuhn, C.; Vorbruggen, W.; Welcker, M.: Radiographic and non-radiographic axial spondyloarthritis are not routinely distinguished in everyday clinical care: an analysis of real-world data from rheumatology practices. In: Rheumatol Int, Bd. 44, Nr. 4, S. 653-661, 2024, ISSN: 1437-160X (Electronic)
0172-8172 (Linking). @article{RN10322b,
title = {Radiographic and non-radiographic axial spondyloarthritis are not routinely distinguished in everyday clinical care: an analysis of real-world data from rheumatology practices},
author = {S. Kleinert and F. Schuch and P. Rapp and M. Ronneberger and J. Wendler and P. Sternad and F. Popp and P. Bartz-Bazzanella and C. Decken and K. Karberg and G. Gauler and P. Wurth and S. Spathling-Mestekemper and C. Kuhn and W. Vorbruggen and M. Welcker},
url = {https://www.ncbi.nlm.nih.gov/pubmed/37805981},
doi = {10.1007/s00296-023-05463-7},
issn = {1437-160X (Electronic)
0172-8172 (Linking)},
year = {2024},
date = {2024-01-01},
journal = {Rheumatol Int},
volume = {44},
number = {4},
pages = {653-661},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Stephan, Marlene; Tascilar, Koray; Yalcin-Mutlu, Melek; Hagen, Melanie; Haschka, Judith; Reiser, Michaela; Hartmann, Fabian; Kleyer, Arnd; Hueber, Axel J; Manger, Bernhard; Figueiredo, Camille; Cobra, Jayme Fogagnolo; Tony, Hans-Peter; Finzel, Stephanie; Kleinert, Stefan; Wendler, Jörg; Schuch, Florian; Ronneberger, Monika; Feuchtenberger, Martin; Fleck, Martin; Manger, Karin; Ochs, Wolfgang; Schmitt-Haendle, Matthias; Lorenz, Hannes Martin; Nüsslein, Hubert; Alten, Rieke; Henes, Joerg; Krüger, Klaus; Schett, Georg; Rech, Jürgen: Physical Function of RA patients Tapering Treatment-A Post Hoc Analysis of the Randomized Controlled RETRO Trial. In: J Clin Med, Bd. 12, Nr. 11, 2023, ISSN: 2077-0383. @article{pmid37297917,
title = {Physical Function of RA patients Tapering Treatment-A Post Hoc Analysis of the Randomized Controlled RETRO Trial},
author = {Marlene Stephan and Koray Tascilar and Melek Yalcin-Mutlu and Melanie Hagen and Judith Haschka and Michaela Reiser and Fabian Hartmann and Arnd Kleyer and Axel J Hueber and Bernhard Manger and Camille Figueiredo and Jayme Fogagnolo Cobra and Hans-Peter Tony and Stephanie Finzel and Stefan Kleinert and Jörg Wendler and Florian Schuch and Monika Ronneberger and Martin Feuchtenberger and Martin Fleck and Karin Manger and Wolfgang Ochs and Matthias Schmitt-Haendle and Hannes Martin Lorenz and Hubert Nüsslein and Rieke Alten and Joerg Henes and Klaus Krüger and Georg Schett and Jürgen Rech},
doi = {10.3390/jcm12113723},
issn = {2077-0383},
year = {2023},
date = {2023-05-01},
journal = {J Clin Med},
volume = {12},
number = {11},
abstract = {Several studies have shown that tapering or stopping disease-modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis (RA) patients in sustained remission is feasible. However, tapering/stopping bears the risk of decline in physical function as some patients may relapse and face increased disease activity. Here, we analyzed the impact of tapering or stopping DMARD treatment on the physical function of RA patients. The study was a post hoc analysis of physical functional worsening for 282 patients with RA in sustained remission tapering and stopping DMARD treatment in the prospective randomized RETRO study. HAQ and DAS-28 scores were determined in baseline samples of patients continuing DMARD (arm 1), tapering their dose by 50% (arm 2), or stopping after tapering (arm 3). Patients were followed over 1 year, and HAQ and DAS-28 scores were evaluated every 3 months. The effect of treatment reduction strategy on functional worsening was assessed in a recurrent-event Cox regression model with a study-group (control, taper, and taper/stop) as the predictor. Two-hundred and eighty-two patients were analyzed. In 58 patients, functional worsening was observed. The incidences suggest a higher probability of functional worsening in patients tapering and/or stopping DMARDs, which is likely due to higher relapse rates in these individuals. At the end of the study, however, functional worsening was similar among the groups. Point estimates and survival curves show that the decline in functionality according to HAQ after tapering or discontinuation of DMARDs in RA patients with stable remission is associated with recurrence, but not with an overall functional decline.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Several studies have shown that tapering or stopping disease-modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis (RA) patients in sustained remission is feasible. However, tapering/stopping bears the risk of decline in physical function as some patients may relapse and face increased disease activity. Here, we analyzed the impact of tapering or stopping DMARD treatment on the physical function of RA patients. The study was a post hoc analysis of physical functional worsening for 282 patients with RA in sustained remission tapering and stopping DMARD treatment in the prospective randomized RETRO study. HAQ and DAS-28 scores were determined in baseline samples of patients continuing DMARD (arm 1), tapering their dose by 50% (arm 2), or stopping after tapering (arm 3). Patients were followed over 1 year, and HAQ and DAS-28 scores were evaluated every 3 months. The effect of treatment reduction strategy on functional worsening was assessed in a recurrent-event Cox regression model with a study-group (control, taper, and taper/stop) as the predictor. Two-hundred and eighty-two patients were analyzed. In 58 patients, functional worsening was observed. The incidences suggest a higher probability of functional worsening in patients tapering and/or stopping DMARDs, which is likely due to higher relapse rates in these individuals. At the end of the study, however, functional worsening was similar among the groups. Point estimates and survival curves show that the decline in functionality according to HAQ after tapering or discontinuation of DMARDs in RA patients with stable remission is associated with recurrence, but not with an overall functional decline. |
Kleinert, Stefan; Rapp, Praxedis; Schuch, Florian; Ronneberger, Monika; Wendler, Joerg; Sternad, Patrizia; Popp, Florian; Bartz-Bazzanella, Peter; Decken, Cay; Karberg, Kirsten; Gauler, Georg; Wurth, Patrick; Späthling-Mestekemper, Susanna; Kuhn, Christoph; Vorbrüggen, Wolfgang; Welcker, Martin: Röntgenologische versus non-röntgenologische axiale Spondyloarthritis - Auch ein Real-World-Klassifikation. In: Deutscher Rheumatologiekongress 2023, 51. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 2023. @article{RN10244,
title = {Röntgenologische versus non-röntgenologische axiale Spondyloarthritis - Auch ein Real-World-Klassifikation},
author = {Stefan Kleinert and Praxedis Rapp and Florian Schuch and Monika Ronneberger and Joerg Wendler and Patrizia Sternad and Florian Popp and Peter Bartz-Bazzanella and Cay Decken and Kirsten Karberg and Georg Gauler and Patrick Wurth and Susanna Späthling-Mestekemper and Christoph Kuhn and Wolfgang Vorbrüggen and Martin Welcker},
doi = {https://dx.doi.org/10.3205/23dgrh184},
year = {2023},
date = {2023-01-01},
journal = {Deutscher Rheumatologiekongress 2023, 51. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh)},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Kleinert, S.; Schuch, F.; Rapp, P.; Ronneberger, M.; Wendler, J.; Sternad, P.; Popp, F.; Bartz-Bazzanella, P.; Decken, C.; Karberg, K.; Gauler, G.; Wurth, P.; Spathling-Mestekemper, S.; Kuhn, C.; Englbrecht, M.; Vorbruggen, W.; Adler, G.; Welcker, M.: Impairment in cognitive function in patients with axial spondyloarthritis and psoriatic arthritis. In: Rheumatol Int, Bd. 43, Nr. 1, S. 89-97, 2023, ISSN: 1437-160X (Electronic)
0172-8172 (Linking). @article{RN10032,
title = {Impairment in cognitive function in patients with axial spondyloarthritis and psoriatic arthritis},
author = {S. Kleinert and F. Schuch and P. Rapp and M. Ronneberger and J. Wendler and P. Sternad and F. Popp and P. Bartz-Bazzanella and C. Decken and K. Karberg and G. Gauler and P. Wurth and S. Spathling-Mestekemper and C. Kuhn and M. Englbrecht and W. Vorbruggen and G. Adler and M. Welcker},
url = {https://www.ncbi.nlm.nih.gov/pubmed/36441274},
doi = {10.1007/s00296-022-05248-4},
issn = {1437-160X (Electronic)
0172-8172 (Linking)},
year = {2023},
date = {2023-01-01},
journal = {Rheumatol Int},
volume = {43},
number = {1},
pages = {89-97},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Kleinert, S.; Burigk, K.; Baltrusch, S.; Ronneberger, M.; Rapp, P.; Wendler, J.; Schuch, F.; Welcker, M.; Decken, C.; Bartz-Bazzanella, P.; Vorbrüggen, W.: RhePORT – Effizienz hinsichtlich personeller Ressourcen und Patientenselektion – Bewährung im Praxisalltag!. In: Deutscher Rheumatologiekongress 2023, 51. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 2023. @article{RN10245,
title = {RhePORT – Effizienz hinsichtlich personeller Ressourcen und Patientenselektion – Bewährung im Praxisalltag!},
author = {S. Kleinert and K. Burigk and S. Baltrusch and M. Ronneberger and P. Rapp and J. Wendler and F. Schuch and M. Welcker and C. Decken and P. Bartz-Bazzanella and W. Vorbrüggen},
doi = {https://dx.doi.org/10.3205/23dgrh236},
year = {2023},
date = {2023-01-01},
journal = {Deutscher Rheumatologiekongress 2023, 51. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh)},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Stephan, M.; Tascilar, K.; Yalcin-Mutlu, M.; Hagen, M.; Haschka, J.; Reiser, M.; Hartmann, F.; Kleyer, A.; Hueber, A. J.; Manger, B.; Figueiredo, C.; Cobra, J. F.; Tony, H. P.; Finzel, S.; Kleinert, S.; Wendler, J.; Schuch, F.; Ronneberger, M.; Feuchtenberger, M.; Fleck, M.; Manger, K.; Ochs, W.; Schmitt-Haendle, M.; Lorenz, H. M.; Nüsslein, H.; Alten, R.; Henes, J.; Krüger, K.; Schett, G.; Rech, J.: Physical Function of RA patients Tapering Treatment-A Post Hoc Analysis of the Randomized Controlled RETRO Trial. In: J Clin Med, Bd. 12, Nr. 11, 2023, ISSN: 2077-0383 (Print)
2077-0383. @article{RN10321,
title = {Physical Function of RA patients Tapering Treatment-A Post Hoc Analysis of the Randomized Controlled RETRO Trial},
author = {M. Stephan and K. Tascilar and M. Yalcin-Mutlu and M. Hagen and J. Haschka and M. Reiser and F. Hartmann and A. Kleyer and A. J. Hueber and B. Manger and C. Figueiredo and J. F. Cobra and H. P. Tony and S. Finzel and S. Kleinert and J. Wendler and F. Schuch and M. Ronneberger and M. Feuchtenberger and M. Fleck and K. Manger and W. Ochs and M. Schmitt-Haendle and H. M. Lorenz and H. Nüsslein and R. Alten and J. Henes and K. Krüger and G. Schett and J. Rech},
doi = {10.3390/jcm12113723},
issn = {2077-0383 (Print)
2077-0383},
year = {2023},
date = {2023-01-01},
journal = {J Clin Med},
volume = {12},
number = {11},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Kleinert, S.; Schuch, F.; Rapp, P.; Ronneberger, M.; Wendler, J.; Sternad, P.; Popp, F.; Bartz-Bazzanella, P.; Decken, C.; Karberg, K.; Gauler, G.; Wurth, P.; Spathling-Mestekemper, S.; Kuhn, C.; Vorbruggen, W.; Welcker, M.: Radiographic and non-radiographic axial spondyloarthritis are not routinely distinguished in everyday clinical care: an analysis of real-world data from rheumatology practices. In: Rheumatol Int, 2023, ISSN: 1437-160X (Electronic) 0172-8172 (Linking). @article{RN10322,
title = {Radiographic and non-radiographic axial spondyloarthritis are not routinely distinguished in everyday clinical care: an analysis of real-world data from rheumatology practices},
author = {S. Kleinert and F. Schuch and P. Rapp and M. Ronneberger and J. Wendler and P. Sternad and F. Popp and P. Bartz-Bazzanella and C. Decken and K. Karberg and G. Gauler and P. Wurth and S. Spathling-Mestekemper and C. Kuhn and W. Vorbruggen and M. Welcker},
url = {https://www.ncbi.nlm.nih.gov/pubmed/37805981},
doi = {10.1007/s00296-023-05463-7},
issn = {1437-160X (Electronic) 0172-8172 (Linking)},
year = {2023},
date = {2023-01-01},
urldate = {2023-01-01},
journal = {Rheumatol Int},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Simon, David; Tascilar, Koray; Kleyer, Arnd; Fagni, Filippo; Krönke, Gerhard; Meder, Christine; Dietrich, Peter; Orlemann, Till; Kliem, Thorsten; Mößner, Johanna; Liphardt, Anna-Maria; Schönau, Verena; Bohr, Daniela; Schuster, Louis; Hartmann, Fabian; Leppkes, Moritz; Ramming, Andreas; Pachowsky, Milena; Schuch, Florian; Ronneberger, Monika; Kleinert, Stefan; Hueber, Axel J; Manger, Karin; Manger, Bernhard; Atreya, Raja; Berking, Carola; Sticherling, Michael; Neurath, Markus F; Schett, Georg: Impact of cytokine inhibitor therapy on the prevalence, seroconversion rate, and longevity of the humoral immune response against SARS-CoV-2 in an unvaccinated cohort. In: Arthritis Rheumatol., Bd. 74, Nr. 5, S. 783–790, 2022. @article{Simon2022-wz,
title = {Impact of cytokine inhibitor therapy on the prevalence, seroconversion rate, and longevity of the humoral immune response against SARS-CoV-2 in an unvaccinated cohort},
author = {David Simon and Koray Tascilar and Arnd Kleyer and Filippo Fagni and Gerhard Krönke and Christine Meder and Peter Dietrich and Till Orlemann and Thorsten Kliem and Johanna Mößner and Anna-Maria Liphardt and Verena Schönau and Daniela Bohr and Louis Schuster and Fabian Hartmann and Moritz Leppkes and Andreas Ramming and Milena Pachowsky and Florian Schuch and Monika Ronneberger and Stefan Kleinert and Axel J Hueber and Karin Manger and Bernhard Manger and Raja Atreya and Carola Berking and Michael Sticherling and Markus F Neurath and Georg Schett},
url = {https://pubmed.ncbi.nlm.nih.gov/34951137/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011429/},
year = {2022},
date = {2022-05-01},
urldate = {2022-05-01},
journal = {Arthritis Rheumatol.},
volume = {74},
number = {5},
pages = {783–790},
publisher = {Wiley},
abstract = {ÖBJECTIVE: To investigate the impact of biologic
disease-modifying antirheumatic drug (bDMARD) treatment on the
prevalence, seroconversion rate, and longevity of the humoral
immune response against SARS-CoV-2 in patients with
immune-mediated inflammatory diseases (IMIDs). METHODS:
Anti-SARS-CoV-2 IgG antibodies were measured in a prospective
cohort of health care professional controls and non-health care
controls and IMID patients receiving no treatment or receiving
treatment with conventional or biologic DMARDs during the first
and second COVID-19 waves. Regression models adjusting for age,
sex, sampling time, and exposure risk behavior were used to
calculate relative risks (RRs) of seropositivity. Seroconversion
rates were assessed in participants with polymerase chain
reaction (PCR)-positive SARS-CoV-2 infection. Antibody response
longevity was evaluated by reassessing participants who tested
positive during the first wave. RESULTS: In this study, 4,508
participants (2,869 IMID patients and 1,639 controls) were
analyzed. The unadjusted RR (0.44 [95% confidence interval
(95% CI) 0.31-0.62]) and adjusted RR (0.50 [95% CI 0.34-0.73])
for SARS-CoV-2 IgG antibodies were significantly lower in IMID
patients treated with bDMARDs compared to non-health care
controls (P < 0.001), primarily driven by treatment with tumor
necrosis factor inhibitors, interleukin-17 (IL-17) inhibitors,
and IL-23 inhibitors. Adjusted RRs for untreated IMID patients
(1.12 [95% CI 0.75-1.67]) and IMID patients receiving
conventional synthetic DMARDs (0.70 [95% CI 0.45-1.08]) were
not significantly different from non-health care controls. Lack
of seroconversion in PCR-positive participants was more common
among bDMARD-treated patients (38.7%) than in non-health care
controls (16%). Overall, 44% of positive participants lost
SARS-CoV-2 antibodies by follow-up, with higher rates in IMID
patients treated with bDMARDs (RR 2.86 [95% CI 1.43-5.74]).
CONCLUSION: IMID patients treated with bDMARDs have a lower
prevalence of SARS-CoV-2 antibodies, seroconvert less frequently
after SARS-CoV-2 infection, and may exhibit a reduced longevity
of their humoral immune response."},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
ÖBJECTIVE: To investigate the impact of biologic
disease-modifying antirheumatic drug (bDMARD) treatment on the
prevalence, seroconversion rate, and longevity of the humoral
immune response against SARS-CoV-2 in patients with
immune-mediated inflammatory diseases (IMIDs). METHODS:
Anti-SARS-CoV-2 IgG antibodies were measured in a prospective
cohort of health care professional controls and non-health care
controls and IMID patients receiving no treatment or receiving
treatment with conventional or biologic DMARDs during the first
and second COVID-19 waves. Regression models adjusting for age,
sex, sampling time, and exposure risk behavior were used to
calculate relative risks (RRs) of seropositivity. Seroconversion
rates were assessed in participants with polymerase chain
reaction (PCR)-positive SARS-CoV-2 infection. Antibody response
longevity was evaluated by reassessing participants who tested
positive during the first wave. RESULTS: In this study, 4,508
participants (2,869 IMID patients and 1,639 controls) were
analyzed. The unadjusted RR (0.44 [95% confidence interval
(95% CI) 0.31-0.62]) and adjusted RR (0.50 [95% CI 0.34-0.73])
for SARS-CoV-2 IgG antibodies were significantly lower in IMID
patients treated with bDMARDs compared to non-health care
controls (P < 0.001), primarily driven by treatment with tumor
necrosis factor inhibitors, interleukin-17 (IL-17) inhibitors,
and IL-23 inhibitors. Adjusted RRs for untreated IMID patients
(1.12 [95% CI 0.75-1.67]) and IMID patients receiving
conventional synthetic DMARDs (0.70 [95% CI 0.45-1.08]) were
not significantly different from non-health care controls. Lack
of seroconversion in PCR-positive participants was more common
among bDMARD-treated patients (38.7%) than in non-health care
controls (16%). Overall, 44% of positive participants lost
SARS-CoV-2 antibodies by follow-up, with higher rates in IMID
patients treated with bDMARDs (RR 2.86 [95% CI 1.43-5.74]).
CONCLUSION: IMID patients treated with bDMARDs have a lower
prevalence of SARS-CoV-2 antibodies, seroconvert less frequently
after SARS-CoV-2 infection, and may exhibit a reduced longevity
of their humoral immune response." |
Simon, David; Tascilar, Koray; Schmidt, Katja; Manger, Bernhard; Weckwerth, Leonie; Sokolova, Maria; Bucci, Laura; Fagni, Filippo; Manger, Karin; Schuch, Florian; Ronneberger, Monika; Hueber, Axel; Steffen, Ulrike; Mielenz, Dirk; Herrmann, Martin; Harrer, Thomas; Kleyer, Arnd; Krönke, Gerhard; Schett, Georg: Humoral and cellular immune responses to SARS-CoV-2 infection
and vaccination in autoimmune disease patients with B cell
depletion. In: Ärthritis Rheumatol.", Bd. 74, Nr. 1, S. 33–37, 2022. @article{Simon2022-nf,
title = {Humoral and cellular immune responses to SARS-CoV-2 infection
and vaccination in autoimmune disease patients with B cell
depletion},
author = {David Simon and Koray Tascilar and Katja Schmidt and Bernhard Manger and Leonie Weckwerth and Maria Sokolova and Laura Bucci and Filippo Fagni and Karin Manger and Florian Schuch and Monika Ronneberger and Axel Hueber and Ulrike Steffen and Dirk Mielenz and Martin Herrmann and Thomas Harrer and Arnd Kleyer and Gerhard Krönke and Georg Schett},
year = {2022},
date = {2022-01-01},
journal = {Ärthritis Rheumatol."},
volume = {74},
number = {1},
pages = {33–37},
publisher = {Wiley},
abstract = {ÖBJECTIVE: B cell depletion is an established therapeutic
principle in a wide range of autoimmune diseases. However, B
cells are also critical for inducing protective immunity after
infection and vaccination. We undertook this study to assess
humoral and cellular immune responses after infection with or
vaccination against SARS-CoV-2 in patients with B cell depletion
and controls who are B cell-competent. METHODS: Antibody
responses (tested using enzyme-linked immunosorbent assay) and T
cell responses (tested using interferon-$gamma$ enzyme-linked
immunospot assay) against the SARS-CoV-2 spike S1 and nucleocapsid proteins were assessed in a limited number of previously infected (n = 6) and vaccinated (n = 8) autoimmune disease patients with B cell depletion, as well as previously infected (n = 30) and vaccinated (n = 30) healthy controls.
RESULTS: As expected, B cell and T cell responses to the
nucleocapsid protein were observed only after infection, while
respective responses to SARS-CoV-2 spike S1 were found after
both infection and vaccination. A SARS-CoV-2 antibody response
was observed in all vaccinated controls (30 of 30 [100%]) but
in none of the vaccinated patients with B cell depletion (0 of
8). In contrast, after SARS-CoV-2 infection, both the patients
with B cell depletion (spike S1, 5 of 6 [83%]; nucleocapsid, 3
of 6 [50%]) and healthy controls (spike S1, 28 of 30 [93%];
nucleocapsid, 28 of 30 [93%]) developed antibodies. T cell
responses against the spike S1 and nucleocapsid proteins were
found in both infected and vaccinated patients with B cell
depletion and in the controls. CONCLUSION: These data show that
B cell depletion completely blocks humoral but not T cell
SARS-CoV-2 vaccination response. Furthermore, limited humoral
immune responses are found after SARS-CoV-2 infection in
patients with B cell depletion."},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
ÖBJECTIVE: B cell depletion is an established therapeutic
principle in a wide range of autoimmune diseases. However, B
cells are also critical for inducing protective immunity after
infection and vaccination. We undertook this study to assess
humoral and cellular immune responses after infection with or
vaccination against SARS-CoV-2 in patients with B cell depletion
and controls who are B cell-competent. METHODS: Antibody
responses (tested using enzyme-linked immunosorbent assay) and T
cell responses (tested using interferon-$gamma$ enzyme-linked
immunospot assay) against the SARS-CoV-2 spike S1 and nucleocapsid proteins were assessed in a limited number of previously infected (n = 6) and vaccinated (n = 8) autoimmune disease patients with B cell depletion, as well as previously infected (n = 30) and vaccinated (n = 30) healthy controls.
RESULTS: As expected, B cell and T cell responses to the
nucleocapsid protein were observed only after infection, while
respective responses to SARS-CoV-2 spike S1 were found after
both infection and vaccination. A SARS-CoV-2 antibody response
was observed in all vaccinated controls (30 of 30 [100%]) but
in none of the vaccinated patients with B cell depletion (0 of
8). In contrast, after SARS-CoV-2 infection, both the patients
with B cell depletion (spike S1, 5 of 6 [83%]; nucleocapsid, 3
of 6 [50%]) and healthy controls (spike S1, 28 of 30 [93%];
nucleocapsid, 28 of 30 [93%]) developed antibodies. T cell
responses against the spike S1 and nucleocapsid proteins were
found in both infected and vaccinated patients with B cell
depletion and in the controls. CONCLUSION: These data show that
B cell depletion completely blocks humoral but not T cell
SARS-CoV-2 vaccination response. Furthermore, limited humoral
immune responses are found after SARS-CoV-2 infection in
patients with B cell depletion." |
Kleinert, S.; Rapp, P.; Schuch, F.; Ronneberger, M.; Wendler, J.; Sternad, P.; Popp, F.; Bartz-Bazzanella, P.; Decken, C. B. Von; Karberg, K.; Gauler, G.; Wurth, P.; Spaethling-Mestekemper, S.; Kuhn, C.; Englbrecht, M.; Vorbrüggen, W.; Adler, G.; Welcker, M.: Cognitive Impairment in axial spondyloarthritis? [abstract]. In: Annals of the Rheumatic Diseases, Bd. 80, Nr. Suppl 1, S. 1274, 2021. @article{RN9667,
title = {Cognitive Impairment in axial spondyloarthritis? [abstract]},
author = {S. Kleinert and P. Rapp and F. Schuch and M. Ronneberger and J. Wendler and P. Sternad and F. Popp and P. Bartz-Bazzanella and C. B. Von Decken and K. Karberg and G. Gauler and P. Wurth and S. Spaethling-Mestekemper and C. Kuhn and M. Englbrecht and W. Vorbrüggen and G. Adler and M. Welcker},
url = {http://ard.bmj.com/content/80/Suppl_1/1274.abstract
https://ard.bmj.com/content/annrheumdis/80/Suppl_1/1274.full.pdf},
doi = {10.1136/annrheumdis-2021-eular.1353},
year = {2021},
date = {2021-01-01},
journal = {Annals of the Rheumatic Diseases},
volume = {80},
number = {Suppl 1},
pages = {1274},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Simon, D.; Tascilar, K.; Fagni, F.; Kronke, G.; Kleyer, A.; Meder, C.; Atreya, R.; Leppkes, M.; Kremer, A. E.; Ramming, A.; Pachowsky, M. L.; Schuch, F.; Ronneberger, M.; Kleinert, S.; Hueber, A. J.; Manger, K.; Manger, B.; Berking, C.; Sticherling, M.; Neurath, M. F.; Schett, G.: SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases. In: Ann Rheum Dis, 2021, ISSN: 1468-2060 (Electronic)
0003-4967 (Linking). @article{RN9669,
title = {SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases},
author = {D. Simon and K. Tascilar and F. Fagni and G. Kronke and A. Kleyer and C. Meder and R. Atreya and M. Leppkes and A. E. Kremer and A. Ramming and M. L. Pachowsky and F. Schuch and M. Ronneberger and S. Kleinert and A. J. Hueber and K. Manger and B. Manger and C. Berking and M. Sticherling and M. F. Neurath and G. Schett},
url = {https://www.ncbi.nlm.nih.gov/pubmed/33958324},
doi = {10.1136/annrheumdis-2021-220461},
issn = {1468-2060 (Electronic)
0003-4967 (Linking)},
year = {2021},
date = {2021-01-01},
journal = {Ann Rheum Dis},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Simon, D.; Tascilar, K.; Kronke, G.; Kleyer, A.; Zaiss, M. M.; Heppt, F.; Meder, C.; Atreya, R.; Klenske, E.; Dietrich, P.; Abdullah, A.; Kliem, T.; Corte, G.; Morf, H.; Leppkes, M.; Kremer, A. E.; Ramming, A.; Pachowsky, M.; Schuch, F.; Ronneberger, M.; Kleinert, S.; Maier, C.; Hueber, A. J.; Manger, K.; Manger, B.; Berking, C.; Tenbusch, M.; Uberla, K.; Sticherling, M.; Neurath, M. F.; Schett, G.: Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion. In: Nat Commun, Bd. 11, Nr. 1, S. 3774, 2020, ISSN: 2041-1723 (Electronic)
2041-1723 (Linking). @article{RN9673,
title = {Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion},
author = {D. Simon and K. Tascilar and G. Kronke and A. Kleyer and M. M. Zaiss and F. Heppt and C. Meder and R. Atreya and E. Klenske and P. Dietrich and A. Abdullah and T. Kliem and G. Corte and H. Morf and M. Leppkes and A. E. Kremer and A. Ramming and M. Pachowsky and F. Schuch and M. Ronneberger and S. Kleinert and C. Maier and A. J. Hueber and K. Manger and B. Manger and C. Berking and M. Tenbusch and K. Uberla and M. Sticherling and M. F. Neurath and G. Schett},
url = {https://www.ncbi.nlm.nih.gov/pubmed/32709909},
doi = {10.1038/s41467-020-17703-6},
issn = {2041-1723 (Electronic)
2041-1723 (Linking)},
year = {2020},
date = {2020-01-01},
journal = {Nat Commun},
volume = {11},
number = {1},
pages = {3774},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Kleinert, Stefan; Schuch, Florian; Rapp, Praxedis; Ronneberger, Monika; Wendler, Joerg; Englbrecht, Matthias: How many of your patients have depressive symptoms? How to assess during routine clinical practice?. In: Ann Rheum Dis, Bd. 78, S. A638, 2019. @article{RN9615,
title = {How many of your patients have depressive symptoms? How to assess during routine clinical practice?},
author = {Stefan Kleinert and Florian Schuch and Praxedis Rapp and Monika Ronneberger and Joerg Wendler and Matthias Englbrecht},
year = {2019},
date = {2019-01-01},
journal = {Ann Rheum Dis},
volume = {78},
pages = {A638},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Kleinert, Stefan; Rapp, Praxedis; Ronneberger, Monika; Wendler, Joerg; Schuch, Florian: Dealing with comorbidities in rheumatoid arthritis with medical assistants. The patients’ opinion on assessment and education by medical assistants during routine clinical practice [abstract]. In: Ann Rheum Dis, Bd. 78, supplement 2, 2019. @article{RN9625,
title = {Dealing with comorbidities in rheumatoid arthritis with medical assistants. The patients’ opinion on assessment and education by medical assistants during routine clinical practice [abstract]},
author = {Stefan Kleinert and Praxedis Rapp and Monika Ronneberger and Joerg Wendler and Florian Schuch},
year = {2019},
date = {2019-01-01},
journal = {Ann Rheum Dis},
volume = {78, supplement 2},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Figueiredo, Camille P; Bang, Holger; Cobra, Jayme Fogagnolo; Englbrecht, Matthias; Hueber, Axel J; Haschka, Judith; Manger, Bernhard; Kleyer, Arnd; Reiser, Michaela; Finzel, Stephanie; Tony, Hans-Peter; Kleinert, Stefan; Wendler, Joerg; Schuch, Florian; Ronneberger, Monika; Feuchtenberger, Martin; Fleck, Martin; Manger, Karin; Ochs, Wolfgang; Schmitt-Haendle, Matthias; Lorenz, Hanns-Martin; Nuesslein, Hubert; Alten, Rieke; Henes, Joerg; Krueger, Klaus; Rech, Jürgen; Schett, Georg: Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic drugs. In: Ann. Rheum. Dis., Bd. 76, Nr. 2, S. 399–407, 2017. @article{Figueiredo2017-hw,
title = {Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic drugs},
author = {Camille P Figueiredo and Holger Bang and Jayme Fogagnolo Cobra and Matthias Englbrecht and Axel J Hueber and Judith Haschka and Bernhard Manger and Arnd Kleyer and Michaela Reiser and Stephanie Finzel and Hans-Peter Tony and Stefan Kleinert and Joerg Wendler and Florian Schuch and Monika Ronneberger and Martin Feuchtenberger and Martin Fleck and Karin Manger and Wolfgang Ochs and Matthias Schmitt-Haendle and Hanns-Martin Lorenz and Hubert Nuesslein and Rieke Alten and Joerg Henes and Klaus Krueger and Jürgen Rech and Georg Schett},
year = {2017},
date = {2017-02-01},
urldate = {2017-02-01},
journal = {Ann. Rheum. Dis.},
volume = {76},
number = {2},
pages = {399–407},
abstract = {ÖBJECTIVE: To perform a detailed analysis of the autoantibody
response against post-translationally modified proteins in
patients with rheumatoid arthritis (RA) in sustained remission
and to explore whether its composition influences the risk for
disease relapse when tapering disease modifying antirheumatic
drug (DMARD) therapy. METHODS: Immune responses against 10
citrullinated, homocitrullinated/carbamylated and acetylated
peptides, as well as unmodified vimentin (control) and cyclic
citrullinated peptide 2 (CCP2) were tested in baseline serum
samples from 94 patients of the RETRO study. Patients were
classified according to the number of autoantibody reactivities
(0-1/10, 2-5/10 and >5/10) or specificity groups (citrullination,
carbamylation and acetylation; 0-3) and tested for their risk to
develop relapses after DMARD tapering. Demographic and
disease-specific parameters were included in multivariate
logistic regression analysis for defining the role of
autoantibodies in predicting relapse. RESULTS: Patients varied in
their antimodified protein antibody response with the extremes
from recognition of no (0/10) to all antigens (10/10). Antibodies
against citrullinated vimentin (51%), acetylated ornithine (46%) and acetylated lysine (37%) were the most frequently observed subspecificities. Relapse risk significantly (p=0.011)
increased from 18% (0-1/10 reactivities) to 34% (2-5/10) and 55% (>5/10). With respect to specificity groups (0-3), relapse risk significantly (p=0.021) increased from 18% (no reactivity)
to 28%, 36% and finally to 52% with one, two or three antibody
specificity groups, respectively. CONCLUSIONS: The data suggest
that the pattern of antimodified protein antibody response
determines the risk of disease relapse in patients with RA
tapering DMARD therapy. TRIAL REGISTRATION NUMBER:
2009-015740-42; Results."},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
ÖBJECTIVE: To perform a detailed analysis of the autoantibody
response against post-translationally modified proteins in
patients with rheumatoid arthritis (RA) in sustained remission
and to explore whether its composition influences the risk for
disease relapse when tapering disease modifying antirheumatic
drug (DMARD) therapy. METHODS: Immune responses against 10
citrullinated, homocitrullinated/carbamylated and acetylated
peptides, as well as unmodified vimentin (control) and cyclic
citrullinated peptide 2 (CCP2) were tested in baseline serum
samples from 94 patients of the RETRO study. Patients were
classified according to the number of autoantibody reactivities
(0-1/10, 2-5/10 and >5/10) or specificity groups (citrullination,
carbamylation and acetylation; 0-3) and tested for their risk to
develop relapses after DMARD tapering. Demographic and
disease-specific parameters were included in multivariate
logistic regression analysis for defining the role of
autoantibodies in predicting relapse. RESULTS: Patients varied in
their antimodified protein antibody response with the extremes
from recognition of no (0/10) to all antigens (10/10). Antibodies
against citrullinated vimentin (51%), acetylated ornithine (46%) and acetylated lysine (37%) were the most frequently observed subspecificities. Relapse risk significantly (p=0.011)
increased from 18% (0-1/10 reactivities) to 34% (2-5/10) and 55% (>5/10). With respect to specificity groups (0-3), relapse risk significantly (p=0.021) increased from 18% (no reactivity)
to 28%, 36% and finally to 52% with one, two or three antibody
specificity groups, respectively. CONCLUSIONS: The data suggest
that the pattern of antimodified protein antibody response
determines the risk of disease relapse in patients with RA
tapering DMARD therapy. TRIAL REGISTRATION NUMBER:
2009-015740-42; Results." |
Figueiredo, C. P.; Bang, H.; Cobra, J. F.; Englbrecht, M.; Hueber, A. J.; Haschka, J.; Manger, B.; Kleyer, A.; Reiser, M.; Finzel, S.; Tony, H. P.; Kleinert, S.; Wendler, J.; Schuch, F.; Ronneberger, M.; Feuchtenberger, M.; Fleck, M.; Manger, K.; Ochs, W.; Schmitt-Haendle, M.; Lorenz, H. M.; Nuesslein, H.; Alten, R.; Henes, J.; Krueger, K.; Rech, J.; Schett, G.: Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic drugs. In: Ann Rheum Dis, Bd. 76, Nr. 2, S. 399-407, 2017, ISSN: 1468-2060 (Electronic)
0003-4967 (Linking). @article{RN8609,
title = {Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic drugs},
author = {C. P. Figueiredo and H. Bang and J. F. Cobra and M. Englbrecht and A. J. Hueber and J. Haschka and B. Manger and A. Kleyer and M. Reiser and S. Finzel and H. P. Tony and S. Kleinert and J. Wendler and F. Schuch and M. Ronneberger and M. Feuchtenberger and M. Fleck and K. Manger and W. Ochs and M. Schmitt-Haendle and H. M. Lorenz and H. Nuesslein and R. Alten and J. Henes and K. Krueger and J. Rech and G. Schett},
url = {https://www.ncbi.nlm.nih.gov/pubmed/27323772
http://ard.bmj.com/content/annrheumdis/76/2/399.full.pdf},
doi = {10.1136/annrheumdis-2016-209297},
issn = {1468-2060 (Electronic)
0003-4967 (Linking)},
year = {2017},
date = {2017-01-01},
journal = {Ann Rheum Dis},
volume = {76},
number = {2},
pages = {399-407},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Haschka, J.; Englbrecht, M.; Hueber, A. J.; Manger, B.; Kleyer, A.; Reiser, M.; Finzel, S.; Tony, H. P.; Kleinert, S.; Feuchtenberger, M.; Fleck, M.; Manger, K.; Ochs, W.; Schmitt-Haendle, M.; Wendler, J.; Schuch, F.; Ronneberger, M.; Lorenz, H. M.; Nuesslein, H.; Alten, R.; Demary, W.; Henes, J.; Schett, G.; Rech, J.: Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study. In: Ann Rheum Dis, Bd. 75, Nr. 1, S. 45-51, 2016, ISSN: 1468-2060 (Electronic)
0003-4967 (Linking). @article{RN7751,
title = {Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study},
author = {J. Haschka and M. Englbrecht and A. J. Hueber and B. Manger and A. Kleyer and M. Reiser and S. Finzel and H. P. Tony and S. Kleinert and M. Feuchtenberger and M. Fleck and K. Manger and W. Ochs and M. Schmitt-Haendle and J. Wendler and F. Schuch and M. Ronneberger and H. M. Lorenz and H. Nuesslein and R. Alten and W. Demary and J. Henes and G. Schett and J. Rech},
url = {http://www.ncbi.nlm.nih.gov/pubmed/25660991},
doi = {10.1136/annrheumdis-2014-206439},
issn = {1468-2060 (Electronic)
0003-4967 (Linking)},
year = {2016},
date = {2016-01-01},
journal = {Ann Rheum Dis},
volume = {75},
number = {1},
pages = {45-51},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Rech, J.; Hueber, A. J.; Finzel, S.; Englbrecht, M.; Haschka, J.; Manger, B.; Kleyer, A.; Reiser, M.; Cobra, J. F.; Figueiredo, C.; Tony, H. P.; Kleinert, S.; Wendler, J.; Schuch, F.; Ronneberger, M.; Feuchtenberger, M.; Fleck, M.; Manger, K.; Ochs, W.; Schmitt-Haendle, M.; Lorenz, H. M.; Nuesslein, H.; Alten, R.; Henes, J.; Krueger, K.; Schett, G.: Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment. In: Ann Rheum Dis, Bd. 75, Nr. 9, S. 1637-44, 2016, ISSN: 1468-2060 (Electronic)
0003-4967 (Linking). @article{RN8206,
title = {Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment},
author = {J. Rech and A. J. Hueber and S. Finzel and M. Englbrecht and J. Haschka and B. Manger and A. Kleyer and M. Reiser and J. F. Cobra and C. Figueiredo and H. P. Tony and S. Kleinert and J. Wendler and F. Schuch and M. Ronneberger and M. Feuchtenberger and M. Fleck and K. Manger and W. Ochs and M. Schmitt-Haendle and H. M. Lorenz and H. Nuesslein and R. Alten and J. Henes and K. Krueger and G. Schett},
url = {https://www.ncbi.nlm.nih.gov/pubmed/26483255
http://ard.bmj.com/content/annrheumdis/75/9/1637.full.pdf},
doi = {10.1136/annrheumdis-2015-207900},
issn = {1468-2060 (Electronic)
0003-4967 (Linking)},
year = {2016},
date = {2016-01-01},
journal = {Ann Rheum Dis},
volume = {75},
number = {9},
pages = {1637-44},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Haschka, J.; Englbrecht, M.; Hueber, A. J.; Manger, B.; Kleyer, A.; Reiser, M.; Finzel, S.; Tony, H. P.; Kleinert, S.; Feuchtenberger, M.; Fleck, M.; Manger, K.; Ochs, W.; Schmitt-Haendle, M.; Wendler, J.; Schuch, F.; Ronneberger, M.; Lorenz, H. M.; Nuesslein, H.; Alten, R.; Demary, W.; Henes, J.; Schett, G.; Rech, J.: Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study. In: Ann Rheum Dis, 2015, ISSN: 0003-4967. @article{RN9102,
title = {Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study},
author = {J. Haschka and M. Englbrecht and A. J. Hueber and B. Manger and A. Kleyer and M. Reiser and S. Finzel and H. P. Tony and S. Kleinert and M. Feuchtenberger and M. Fleck and K. Manger and W. Ochs and M. Schmitt-Haendle and J. Wendler and F. Schuch and M. Ronneberger and H. M. Lorenz and H. Nuesslein and R. Alten and W. Demary and J. Henes and G. Schett and J. Rech},
url = {https://ard.bmj.com/content/annrheumdis/75/1/45.full.pdf},
doi = {10.1136/annrheumdis-2014-206439},
issn = {0003-4967},
year = {2015},
date = {2015-01-01},
journal = {Ann Rheum Dis},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Rech, Juergen; Ronneberger, Monika; Englbrecht, Matthias; Finzel, Stephanie; Katzenbeisser, Julia; Manger, Karin; Manger, Bernhard; Schett, Georg: Successful treatment of adult-onset Still's disease refractory
to TNF and IL-1 blockade by IL-6 receptor blockade. In: Änn. Rheum. Dis.", Bd. 70, Nr. 2, S. 390–392, 2011. @article{Rech2011-tv,
title = {Successful treatment of adult-onset Still's disease refractory
to TNF and IL-1 blockade by IL-6 receptor blockade},
author = {Juergen Rech and Monika Ronneberger and Matthias Englbrecht and Stephanie Finzel and Julia Katzenbeisser and Karin Manger and Bernhard Manger and Georg Schett},
year = {2011},
date = {2011-02-01},
journal = {Änn. Rheum. Dis."},
volume = {70},
number = {2},
pages = {390–392},
publisher = {BMJ},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Wollheim, Frank A.; Ronneberger, Monika: Entheropathic Arthritis. In: Kelley's Textbook of Rheumatology, 9th Edition, 2011. @incollection{Woll2011Ronn,
title = {Entheropathic Arthritis},
author = {Frank A. Wollheim and Monika Ronneberger},
year = {2011},
date = {2011-01-01},
booktitle = {Kelley's Textbook of Rheumatology, 9th Edition},
edition = {9},
keywords = {},
pubstate = {published},
tppubtype = {incollection}
}
|
Grunke, Mathias; Antoni, Christian E; Kavanaugh, Arthur; Hildebrand, Verena; Dechant, Claudia; Schett, Georg; Manger, Bernhard; Ronneberger, Monika: Standardization of joint examination technique leads to a
significant decrease in variability among different examiners. In: J. Rheumatol., Bd. 37, Nr. 4, S. 860–864, 2010. @article{Grunke2010-fp,
title = {Standardization of joint examination technique leads to a
significant decrease in variability among different examiners},
author = {Mathias Grunke and Christian E Antoni and Arthur Kavanaugh and Verena Hildebrand and Claudia Dechant and Georg Schett and Bernhard Manger and Monika Ronneberger},
year = {2010},
date = {2010-04-01},
journal = {J. Rheumatol.},
volume = {37},
number = {4},
pages = {860–864},
publisher = {The Journal of Rheumatology},
abstract = {ÖBJECTIVE: To reduce the amount of variability among assessors,
we conducted joint examination standardization seminars in
conjunction with multicenter clinical trials for patients with
rheumatoid arthritis (RA). The examination techniques used were
based on the recommendations of the European League Against
Rheumatism (EULAR). METHODS: To evaluate the effect of
standardization, participants at the seminars examined a given
patient with RA before and after they were made familiar with
the EULAR examination technique. The number of tender and
swollen joints as well as the variance among the examiners
before and after the training were compared. Joints were rated
positive or negative for tenderness and swelling without
grading. RESULTS: Overall, 553 individuals from a variety of
countries in Europe, North America, Asia, and Australia
participated. Examiners included different kinds of health
professionals, mainly physicians and nurses. We found a
substantial variance among examiners before the training in the
standardized method. This variance could be significantly
reduced by the training. We also found that the number of joints
considered active was markedly reduced after the training.
CONCLUSION: Standardized joint examination training
significantly reduces variability among different assessors."},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
ÖBJECTIVE: To reduce the amount of variability among assessors,
we conducted joint examination standardization seminars in
conjunction with multicenter clinical trials for patients with
rheumatoid arthritis (RA). The examination techniques used were
based on the recommendations of the European League Against
Rheumatism (EULAR). METHODS: To evaluate the effect of
standardization, participants at the seminars examined a given
patient with RA before and after they were made familiar with
the EULAR examination technique. The number of tender and
swollen joints as well as the variance among the examiners
before and after the training were compared. Joints were rated
positive or negative for tenderness and swelling without
grading. RESULTS: Overall, 553 individuals from a variety of
countries in Europe, North America, Asia, and Australia
participated. Examiners included different kinds of health
professionals, mainly physicians and nurses. We found a
substantial variance among examiners before the training in the
standardized method. This variance could be significantly
reduced by the training. We also found that the number of joints
considered active was markedly reduced after the training.
CONCLUSION: Standardized joint examination training
significantly reduces variability among different assessors." |
Ronneberger, M; Janka, R; Schett, G; Manger, B: Can MRI substitute for biopsy in eosinophilic fasciitis?. In: Änn. Rheum. Dis.", Bd. 68, Nr. 10, S. 1651–1652, 2009. @article{Ronneberger2009-hb,
title = {Can MRI substitute for biopsy in eosinophilic fasciitis?},
author = {M Ronneberger and R Janka and G Schett and B Manger},
year = {2009},
date = {2009-10-01},
journal = {Änn. Rheum. Dis."},
volume = {68},
number = {10},
pages = {1651–1652},
publisher = {BMJ},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
